Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.
Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.
复制标题
DOI:
10.1016/j.pain.2013.02.026
复制
发表时间:
2013-07
期刊:
影响因子:
7.4
通讯作者:
Mayer EA
中科院分区:
文献类型:
--
作者:
Jarcho JM;Feier NA;Bert A;Labus JA;Lee M;Stains J;Ebrat B;Groman SM;Tillisch K;Brody AL;London ED;Mandelkern MA;Mayer EA
Central sensitization and dysregulation of peripheral substance P and neurokinin-1 receptor (NK-1R) signaling are associated with chronic abdominal pain in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Although positron emission tomography (PET) has demonstrated that patients with injury-related chronic pain have diminished NK-1R availability in the brain, it is unknown whether these deficits are present in IBD and IBS patients, who have etiologically distinct forms of non-injury-related chronic pain. This study's aim was to determine if patients with IBD or IBS exhibit deficits in brain expression of NK-1Rs relative to healthy controls (HCs), the extent to which expression patterns differ across patient populations, and if these patterns differentially relate to clinical parameters. PET with [18F]SPA-RQ was used to measure NK-1R availability by quantifying binding potential (BP) in the 3 groups. Exploratory correlation analyses were performed to detect associations between NK-1R BP and physical symptoms. Compared to HCs, IBD patients had NK-1R BP deficits across a widespread network of cortical and subcortical regions. IBS patients had similar, but less pronounced deficits. BP in a subset of these regions was robustly related to discrete clinical parameters in each patient population. Widespread deficits in NK-1R BP occur in IBD and, to a lesser extent, IBS; however, discrete clinical parameters relate to NK-1R BP in each patient population. This suggests that potential pharmacological interventions that target NK-1R signaling may be most effective for treating distinct symptoms in IBD and IBS.
登录
查看更多内容
影响因子:
5.3
作者:
Bester, H;De Felipe, C;Hunt, SP
通讯作者:
Hunt, SP
影响因子:
24.5
作者:
Chang, L;Munakata, J;Matin, K
通讯作者:
Matin, K
影响因子:
5.7
作者:
Craggs, Jason G.;Price, Donald D.;Robinson, Michael M.
通讯作者:
Robinson, Michael M.
影响因子:
24.5
作者:
Elsenbruch, S.;Rosenberger, C.;Gizewski, E. R.
通讯作者:
Gizewski, E. R.
影响因子:
5.3
作者:
Baliki, Marwan N.;Chialvo, Dante R.;Apkarian, A. Vania
通讯作者:
Apkarian, A. Vania